Analyst Ratings January 26, 2026

H.C. Wainwright Cuts electroCore Price Target to $18, Cites Rising Expenses and Litigation Costs

Brokerage keeps a Buy rating even as preliminary 2025 results show revenue growth and tightening cash balances

By Sofia Navarro ECOR
H.C. Wainwright Cuts electroCore Price Target to $18, Cites Rising Expenses and Litigation Costs
ECOR

H.C. Wainwright reduced its 12-month price target on electroCore Inc. to $18 from $25 while retaining a Buy rating. The adjustment follows electroCore's Jan. 20, 2026 preliminary results showing 2025 revenue of $31.8-$32.0 million, a 26% increase year-over-year, and fourth-quarter revenue of $9.0-$9.2 million, up 30% from Q4 2024. The analyst cited higher operating costs, increased interest expense, and expected litigation fees as reasons for the lower target. electroCore ended 2025 with $11.6 million in cash and plans to publish full results in March 2026.

Key Points

  • H.C. Wainwright reduced its price target on electroCore to $18 from $25 but maintained a Buy rating - sectors impacted include health care devices and small-cap equities.
  • electroCore reported preliminary 2025 revenue of $31.8-$32.0 million, a 26% year-over-year increase, and Q4 2025 revenue of $9.0-$9.2 million, up 30% - this affects medtech revenue growth expectations.
  • Year-end cash was $11.6 million versus $13.2 million at Q3 end, implying a quarterly cash burn of about $1.6 million, relevant to balance-sheet resilience and financing considerations.

H.C. Wainwright has lowered its price target on electroCore Inc. (NASDAQ: ECOR) to $18.00 from $25.00, while leaving its rating on the stock at Buy. The firm pointed to a combination of rising operating costs, greater interest expense and anticipated legal fees as the drivers behind the downward revision.

The move follows electroCore's Jan. 20, 2026 announcement of preliminary results for fiscal year 2025. Management reported full-year revenue in a band of $31.8 million to $32.0 million, which represents a 26% increase compared with the prior year. That range sits in line with the midpoint of the company's prior guidance of $31.5 million to $32.5 million.

For the fourth quarter of 2025, electroCore disclosed preliminary revenue of $9.0 million to $9.2 million, a 30% gain versus the same quarter in 2024. Management attributed the year-over-year rise in part to strong performance across its prescription device and health and wellness segments.

Despite those revenue gains, the company reported a lower cash balance at year-end. electroCore closed 2025 with $11.6 million in cash, down from $13.2 million at the end of the third quarter, implying a quarterly cash burn of roughly $1.6 million between Q3 and year-end. The company also reported a net loss for the third quarter of 2025.

In explaining its decision to reduce the price target, H.C. Wainwright highlighted rising operating expenses and higher interest costs. The firm also factored in expected litigation-related fees in the range of $1.5 million to $2.0 million. Those cost pressures prompted the brokerage to lower its valuation despite retaining a positive view on the company's prospects.

H.C. Wainwright's modeling projects electroCore's revenue to reach $42 million in 2026 and to expand further to $121 million by 2032. electroCore management has scheduled the release of complete financial statements for March 2026.

Management reiterated its expectation to report record full-year revenue for 2025 at approximately $31.8 million to $32.0 million, consistent with the preliminary figures. The company said fourth-quarter revenue for 2025 is expected to be around $9.0 million to $9.2 million, marking a 30% improvement relative to Q4 2024. The firm has provided forward guidance that signals continued revenue growth and operational expansion as it pursues broader product offerings and greater market presence.


Context and market positioning

At the time of the analyst revision, electroCore was trading at $7.47, which places the stock well below the analyst consensus target range of $12.00 to $25.28. The company's share performance has nonetheless delivered returns of more than 66% year-to-date, as reported by InvestingPro data.

Investors will be watching the company's full 2025 financial report in March 2026 for detailed results and updated guidance, and will also monitor cash flows, expense trends and any further information regarding litigation costs.

Risks

  • Rising operating expenses, higher interest expense and anticipated litigation fees of $1.5-$2.0 million may pressure profitability and cash — impacting the health care devices sector and small-cap capital markets.
  • A declining cash balance and ongoing quarterly cash burn introduce financing and liquidity risk if revenue growth or margins do not sustain the current pace - relevant to investors monitoring balance-sheet stability.
  • The company reported a net loss in Q3 2025, which combined with elevated costs could delay path to consistent profitability and affect valuation assumptions used by analysts.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026